Malignant hyperthermia domain in the regulation of Ca2+ release channel (Ryanodine receptor)

Trends in Cardiovascular Medicine

Volumn 7, Issue 8, 1997, Pages 312-316

  Zorzato, Francesco ^a   Ronjat, Michel ^b   Treves, Susan ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b URA 520 du CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; RYANODINE RECEPTOR;

BODY TEMPERATURE; CALCIUM TRANSPORT; GENE MUTATION; HUMAN; INHALATION ANESTHESIA; MALIGNANT HYPERTHERMIA; MUSCLE HYPOTONIA; MUSCLE RIGIDITY; PRIORITY JOURNAL; REVIEW; SARCOPLASMIC RETICULUM; SKELETAL MUSCLE;

EID: 0030698725     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(97)00085-6     Document Type: Review

References (34)

1. Ahern GP, Junankar PR, Dulhunty AF: 1997. Subconductance states in single-channel activity of skeletal muscle ryanodine receptors after removal of FKBP12. Biophys J 72:146-162.
2. 2+ signaling. Nature 361:315-325.
3. Coronado R, Morissette J, Sukhareva M, Vaughan DM: 1994. Structure and function of ryanodine receptors. Am J Physiol 266: 1485-1504.
4. Fujii J, Otsu K, Zorzato F, et al.: 1991. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 253:448-451.
5. Gillard EF, Otsu K, Fujii J, et al.: 1991. A substitution for arginine 614 in the ryanodine receptor is potentially causative of malignant hyperthermia. Genomics 11:751-755.
6. Gillard EF, Otsu K, Fujii J, et al.: 1992. Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia. Genomics 13:1247-1254.
7. Gronert GA: 1980. Malignant hyperthermia. Anesthesiology 53:395-423.
8. 2+-release channel in malignant hyperthermia. J Biol Chem 267: 6702-6709.
9. Iaizzo PA, Klein W, Lehamann-Horn F: 1988. Fura-2 detected myoplasmic concentration and its correlation with contracture force in skeletal muscle from normal and malignant hyperthermia susceptible pigs. Pflugers Arch 411:648-653.
10. 2+ release in calpain treated rabbit skinned muscle fibers. Biochem Biophys Res Commun 185: 713-718.
11. Iles DE, Lehmann-Horn F, Scherer SW, et al.: 1994. Localization of the gene encoding the subunit of the L-type voltage channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum Mol Genet 3:969-975.
12. 2+ potentiates calcium release during depolarization of frog skeletal muscle. J Gen Physiol 100:137-154.
13. Jayaraman T, Brillantes AM, Timmerman AP, et al.: 1992. FK506 binding protein associated with the calcium release channel (ryanodine receptor). J Biol Chem 267:9474-9477.
14. Keating KE, Quane KA, Manning BM, et al.: 1994. Detection a novel RYR1 mutation in four malignant hyperthermia pedigrees. Hum Mol Genet 3:1855-1858.
15. 2+ release in skeletal muscle fibres of the toad. J Physiol (Lond) 434:507-528.
16. Levitt RC, Dickers A, Meyers S, et al.: 1992. Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. Genomics 14:562-566.
17. Lopez JR, Alamo L, Caputo C, et al.: 1985. Intracellular ionized calcium concentration in muscles from humans with malignant hyperthermia. Muscle Nerve 8:355-358.
18. 2+ release channel. J Biol Chem 268:13,765-13,768.
19. 2+ release channels and their regulation by endogenous effectors. Annu Rev Physiol 56:485-508.
20. 2+, and adenine nucleotide. Biochemistry 25:236-244.
21. Menegazzi P, Larini F, Treves S, Guerrini R, Quadroni M, Zorzato F: 1994. Identification and characterization of three calmodulin binding sites of the skeletal muscle ryanodine receptor. Biochemistry 33:9078-9084.
22. 2+ regulation defects. Physiol Rev 76:537-591.
23. O'Driscoll S, McCarthy TV, Eichinger HM, et al.: 1996. Calmodulin sensitivity of the sarcoplasmic reticulum ryanodine receptor from normal and malignant hyperthermia-susceptible muscle. Biochem J 319:421-426.
24. Quane KA, Healy JM, Keating KE, et al.: 1993. Mutations in the ryanodine receptor gene in the central core disease and malignant hyperthermia. Nat Genet 5:51-55.
25. Quane KA, Keating KE, Manning BM, et al.: 1994. Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies. Hum Mol Genet 3: 471-476.
26. Rios E, Pizarro G: 1991. Voltage sensor of excitation-contraction coupling in skeletal muscle. Physiol Rev 71:849-907.
27. Shuaib A, Paasuke RT, Brownell AK: 1987. Central core disease. Medicine 66:389-396.
28. Sudbrak R, Procaccio V, Klausnitzer M, et al.: 1995. Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. Am J Hum Genet 56:684-691.
29. Takeshima T, Nishimura S, Matsumoto T, et al.: 1989. Primary structure and expression from complementary ona of skeletal muscle ryanodine receptor. Nature 339:439-445.
30. 2+ release channel (ryanodine receptor). Biophys J 69:106-119.
31. Wagenknecht T, Radermarcher M: 1995. Three-dimensional architecture of the skeletal muscle ryanodine receptor. FEBS Lett 369:43-46.
32. Zhang Y, Chen HS, Khanna VK, et al.: 1993. A mutation in the human ryanodine receptor associated with central core disease. Nat Genet 5:46-50.
33. 2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. J Biol Chem 265:2244-2256.
34. 2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. J Biol Chem 271: 22,759-22,763.